The phrase "advantages for the development of" is correct and usable in written English.
You can use it when discussing the benefits or positive aspects that contribute to the growth or progress of a particular subject or field.
Example: "The new policy presents several advantages for the development of renewable energy technologies."
Alternatives: "benefits for the advancement of" or "gains for the progress of".
This potential reduction in hardware offers important advantages for the development of a practical multiple view X-ray scanner.
They highlight, after examining 28 such variables, that foreclosures, problem landlords and broken street lights represent "ecological advantages" for the development of open-air illegal drug markets.
This approach offers tremendous cost- and time-sparing advantages for the development of next-generation therapeutic antibodies.
The design of OpenMRS offers a number of advantages for the development of research data management tools.
Our previous and current studies strongly indicate the advantages of the development of TLR8-targeted immunity for anti-tumor immunotherapy.
One of the advantages of ESI is that it can be readily coupled to HPLC, offering a great advantage for the development of LC/ESI MS/MS assays.
Their advantage for the development of drugs comes from the synergistic interactions of their components and their innate affinity for biological receptors [ 7].
In contrast, LFP recordings can readily remain stable for many months, which is an important advantage for the development of neuronal prosthesis (Andersen et al. 2004).
However, there was a survival advantage for the development of rash (HR for survival by skin toxicity in cetuximab-treated patients 0.42 (95% CI, 0.21 0.86)).
Conjugated polymers such as polyaniline (PANi), polypyrrole (Ppy), and poly 3,4-ethylenedioxythiophene) (poly 3,4-ethylenedioxythiophene for the develoPEDOT offerssue engreaterng scadvantagepecially for neural regenerathen developmentelectrical cofductissue [ 1– 4].
The present paper has taken advantage of the development of a monoclonal specific for the ER βcx/ β2 splice variant (Saunders et al, 2002a) to determine whether expression of this isoform influences response to anti-oestrogen therapy as has been claimed by others (Saji et al, 2002a, 2002b).
